May 25, 2023
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
May 9, 2023
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
April 3, 2023
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 2, 2023
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
Xilio Therapeutics to Present at Upcoming Investor Conferences
February 16, 2023
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit
February 2, 2023
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day